Researchers at EPFL and MIT have introduced BindCraft, an AI-driven pipeline that designs functional protein binders in a single computational shot. Departing from traditional low-efficiency experimental screening, BindCraft achieves strong binding affinity across diverse targets, including cell-surface receptors, allergens, and nucleases like CRISPR-Cas9. The method produces effective binders within a small library of designs without additional optimization. Published in Nature, BindCraft is openly licensed for commercial use, aiming to accelerate therapeutics development by enabling protein design accessible to non-computational biologists.